Susquehanna International Group, LLP Bio N Tech Se Put Options Transaction History

Susquehanna International Group, LLP

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$78.36 - $124.66 $8.74 Million - $13.9 Million	111,600 Added 49.36%	337,700 $40.1 Million
Q2 2024 Aug 15, 2024	SELL	$80.36 - $102.87 $19.1 Million - $24.5 Million	-237,800 Reduced 51.26%	226,100 $18.2 Million
Q1 2024 May 07, 2024	BUY	$88.96 - $112.35 $6.34 Million - $8.01 Million	71,300 Added 18.16%	463,900 $42.8 Million
Q4 2023 Feb 14, 2024	SELL	$90.91 - $112.75 $5.11 Million - $6.34 Million	-56,200 Reduced 12.52%	392,600 $41.4 Million
Q3 2023 Nov 14, 2023	BUY	$98.5 - $125.08 $1.92 Million - $2.44 Million	19,500 Added 4.54%	448,800 $48.8 Million
Q2 2023 Aug 11, 2023	BUY	$102.58 - $129.66 $2.44 Million - $3.09 Million	23,800 Added 5.87%	429,300 $46.3 Million
Q1 2023 May 16, 2023	SELL	$122.57 - $153.67 $45.3 Million - $56.8 Million	-369,300 Reduced 47.66%	405,500 $50.5 Million
Q4 2022 Feb 14, 2023	BUY	$118.43 - $186.05 $6.83 Million - $10.7 Million	57,700 Added 8.05%	774,800 $116 Million
Q3 2022 Nov 14, 2022	SELL	$127.65 - $183.11 $47.7 Million - $68.4 Million	-373,500 Reduced 34.25%	717,100 $96.7 Million

358

38.4M

2.45M

2.29M

Ticker BNTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 242,684,992
Market Cap $24.2B
Description
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.